scholarly journals Deciphering the in vivo Dynamic Proteomics of Mesenchymal Stem Cells in Critical Limb Ischemia

2021 ◽  
Vol 9 ◽  
Author(s):  
Yipeng Du ◽  
Xiaoting Li ◽  
Wenying Yan ◽  
Zhaohua Zeng ◽  
Dunzheng Han ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Protein Synthesis ◽  
Critical Limb Ischemia ◽  
Click Reaction ◽  
Limb Ischemia ◽  
Trna Synthetase ◽  
Doppler Imaging

ObjectiveRegenerative therapy using mesenchymal stem cells (MSC) is a promising therapeutic method for critical limb ischemia (CLI). To understand how the cells are involved in the regenerative process of limb ischemia locally, we proposed a metabolic protein labeling method to label cell proteomes in situ and then decipher the proteome dynamics of MSCs in ischemic hind limb.Methods and ResultsIn this study, we overexpressed mutant methionyl-tRNA synthetase (MetRS), which could utilize azidonorleucine (ANL) instead of methionine (Met) during protein synthesis in MSCs. Fluorescent non-canonical amino-acid tagging (FUNCAT) was performed to detect the utilization of ANL in mutant MSCs. Mice with hindlimb ischemia (HLI) or Sham surgery were treated with MetRSmut MSCs or PBS, followed by i.p. administration of ANL at days 0, 2 6, and 13 after surgery. FUNCAT was also performed in hindlimb tissue sections to demonstrate the incorporation of ANL in transplanted cells in situ. At days 1, 3, 7, and 14 after the surgery, laser doppler imaging were performed to detect the blood reperfusion of ischemic limbs. Ischemic tissues were also collected at these four time points for histological analysis including HE staining and vessel staining, and processed for click reaction based protein enrichment followed by mass spectrometry and bioinformatics analysis. The MetRSmut MSCs showed strong green signal in cell culture and in HLI muscles as well, indicating efficient incorporation of ANL in nascent protein synthesis. By 14 days post-treatment, MSCs significantly increased blood reperfusion and vessel density, while reducing inflammation in HLI model compared to PBS. Proteins enriched by click reaction were distinctive in the HLI group vs. the Sham group. 34, 31, 49, and 26 proteins were significantly up-regulated whereas 28, 32, 62, and 27 proteins were significantly down-regulated in HLI vs. Sham at days 1, 3, 7, and 14, respectively. The differentially expressed proteins were more pronounced in the pathways of apoptosis and energy metabolism.ConclusionIn conclusion, mutant MetRS allows efficient and specific identification of dynamic cell proteomics in situ, which reflect the functions and adaptive changes of MSCs that may be leveraged to understand and improve stem cell therapy in critical limb ischemia.

scholarly journals Comparative analysis of mouse bone marrow and adipose tissue mesenchymal stem cells for critical limb ischemia cell therapy

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Pegah Nammian ◽  
Seyedeh-Leili Asadi-Yousefabad ◽  
Sajad Daneshi ◽  
Mohammad Hasan Sheikhha ◽  
Seyed Mohammad Bagher Tabei ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Adipose Tissue ◽  
Cell Therapy ◽  
Femoral Artery ◽  
Critical Limb Ischemia ◽  
Limb Ischemia

Abstract Introduction Critical limb ischemia (CLI) is the most advanced form of peripheral arterial disease (PAD) characterized by ischemic rest pain and non-healing ulcers. Currently, the standard therapy for CLI is the surgical reconstruction and endovascular therapy or limb amputation for patients with no treatment options. Neovasculogenesis induced by mesenchymal stem cells (MSCs) therapy is a promising approach to improve CLI. Owing to their angiogenic and immunomodulatory potential, MSCs are perfect candidates for the treatment of CLI. The purpose of this study was to determine and compare the in vitro and in vivo effects of allogeneic bone marrow mesenchymal stem cells (BM-MSCs) and adipose tissue mesenchymal stem cells (AT-MSCs) on CLI treatment. Methods For the first step, BM-MSCs and AT-MSCs were isolated and characterized for the characteristic MSC phenotypes. Then, femoral artery ligation and total excision of the femoral artery were performed on C57BL/6 mice to create a CLI model. The cells were evaluated for their in vitro and in vivo biological characteristics for CLI cell therapy. In order to determine these characteristics, the following tests were performed: morphology, flow cytometry, differentiation to osteocyte and adipocyte, wound healing assay, and behavioral tests including Tarlov, Ischemia, Modified ischemia, Function and the grade of limb necrosis scores, donor cell survival assay, and histological analysis. Results Our cellular and functional tests indicated that during 28 days after cell transplantation, BM-MSCs had a great effect on endothelial cell migration, muscle restructure, functional improvements, and neovascularization in ischemic tissues compared with AT-MSCs and control groups. Conclusions Allogeneic BM-MSC transplantation resulted in a more effective recovery from critical limb ischemia compared to AT-MSCs transplantation. In fact, BM-MSC transplantation could be considered as a promising therapy for diseases with insufficient angiogenesis including hindlimb ischemia.

Angiogenic and regenerative potential of mesenchymal stem cells in critical limb ischemia: A review of in vitro and in vivo evidence

Cytotherapy ◽  
2021 ◽  
Vol 23 (5) ◽  
pp. S68
Author(s):  
C.L. Sossa ◽  
L. Lozano Navarro ◽  
X. Chen ◽  
M.L. Luna-Gonzalez ◽  
M.L. Arango-Rodriguez
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Critical Limb Ischemia ◽  
Limb Ischemia

scholarly journals Transplantation of Human Placenta-Derived Mesenchymal Stem Cells Alleviates Critical Limb Ischemia in Diabetic Nude Rats

2017 ◽  
Vol 26 (1) ◽  
pp. 45-61 ◽  
Author(s):  
Lu Liang ◽  
Zongjin Li ◽  
Tao Ma ◽  
Zhibo Han ◽  
Wenjing Du ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Human Placenta ◽  
Critical Limb Ischemia ◽  
Limb Ischemia ◽  
Vascular Density ◽  
Therapeutic Effects ◽  
Differentiation Potential

Neovasculogenesis induced by stem cell therapy is an innovative approach to improve critical limb ischemia (CLI) in diabetes. Mesenchymal stem cells (MSCs) are ideal candidates due to their angiogenic and immunomodulatory features. The aim of this study is to determine the therapeutic effects of human placenta-derived MSCs (P-MSCs) on diabetic CLI, with or without exogenous insulin administration, and the underlying mechanism of any effect. A series of in vitro experiments were performed to assess the stemness and vasculogenic activity of P-MSCs. P-MSCs were intramuscularly injected at two different doses with and without the administration of insulin. The efficacy of P-MSC transplantation was evaluated by ischemia damage score, ambulatory score, laser Doppler perfusion image (LDPI), capillary, and vascular density. In vivo imaging was applied to track the implanted P-MSCs. In vivo differentiation and in situ secretion of angiogenic cytokines were determined. In vitro experimental outcomes showed the differentiation potential and potent paracrine effect of P-MSCs. P-MSCs survived in vivo for at least 3 weeks and led to the acceleration of ischemia recovery, due to newly formed capillaries, increased arterioles, and secretion of various proangiogenic factors. P-MSCs participate in angiogenesis and vascularization directly through differentiation and cytokine expression.

scholarly journals Preclinical Evaluation of Bone Marrow Mesenchymal Stem Cells Overexpressing MicroRNA-126 to Treat Critical Limb Ischemia

2021 ◽  
Author(s):  
Pegah Nammian ◽  
Seyedeh-Leili Asadi-Yousefabad ◽  
Sajad Daneshi ◽  
Jafar Fallahi ◽  
Seyed Mohammad Bagher Tabei ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Effective Treatment ◽  
Femoral Artery ◽  
Critical Limb Ischemia ◽  
Limb Ischemia ◽  
Current Therapy ◽  
Angiogenic Potential ◽  
Paracrine Secretion

Abstract Introduction: Critical limb ischemia (CLI) considered as the most severe form of peripheral artery disease (PAD). Current therapy for CLI are surgical reconstruction and endovascular therapy or limb amputation (for patients with no treatment options). Neovasculogenesis induced by stem cells including mesenchymal stem cells (MSCs) therapy is a promising approach to treat CLI. But this method of treatment faces challenges such as: MSCs survival and paracrine secretion. MicroRNAs are post transcriptional regulatory molecules that regulate many biological processes including VEGF pathway. MicroRNAs could be used to increase viability and angiogenic potential of MSCs. This study was conducted to reinforce and increase the angiogenic potential of BM-MSCs by using microRNA-126 and evaluate the effect of this stem cell gene therapy on treatment of ischemic tissues in CLI mouse models. Methods: BM-MSCs were isolated from male C57 BL/6 inbred mice and characterized by morphology, flow cytometry, differentiation to osteocyte and adipocyte. Transformed BM-MSCs containing miR-126 were produced by using lentiviral vector. Then femoral artery ligation and total excision of the femoral artery was performed on C57BL/6 mice to create CLI model. Animals were allocated to control, BM-MSCs, virus and BM-MSCs miR-126 groups and defined number of the cells and virus were injected 24 h after surgery. In order to determine in vitro and in vivo effects, the following tests were performed: wound healing assay, behavioral tests including: Tarlov, Ischemia, Modified ischemia, Function and the grade of limb necrosis scores, donor cell survival assay, real-time PCR and histological analysis. Results: Results indicated that during 28 days after transplantation, BM-MSCs and virus groups had an enhancing effect on angiogenesis. BM-MSCs miR-126 group had remarkable effect on endothelial cell migration, muscle restructure, functional improvements and neovascularization in ischemic tissues and led to more effective treatment. In vivo evaluation showed that miR-126 could increase BM-MSCs survival and paracrine secretion of angiogenic factors such as VEGF, and led to remarkable functional improvements and neovascularization in ischemic tissues. Conclusions: According to the obtained results, it could concluded that combination of BM-MSCs and miR-126 leads to more effective recovery from critical limb ischemia compared to using them alone. In fact, miR-126 can be used as a strong modifier to reinforce the angiogenic potential of BM-MSCs, leading to more effective treatment for CLI.

In vivo osteogenic differentiation of human turbinate mesenchymal stem cells in an injectable in situ-forming hydrogel

Biomaterials ◽  
2014 ◽  
Vol 35 (20) ◽  
pp. 5337-5346 ◽  
Author(s):  
Jin Seon Kwon ◽  
Sung Won Kim ◽  
Doo Yeon Kwon ◽  
Seung Hun Park ◽  
A. Reum Son ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Osteogenic Differentiation ◽  
In Situ Forming

Feasibility of autologous mesenchymal stem cells therapy for patients with no-option critical limb ischemia

Cytotherapy ◽  
2017 ◽  
Vol 19 (5) ◽  
pp. S186-S187
Author(s):  
S. Mohamed ◽  
L. Howard ◽  
A. Duffy ◽  
A. Finnerty ◽  
M. Holohan ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Critical Limb Ischemia ◽  
Limb Ischemia ◽  
Stem Cells Therapy ◽  
Autologous Mesenchymal Stem Cells

Abstract 182: Increased Adipose-Derived Mesenchymal Stem Cells Counts and Pro-B-Type Natriuretic Peptide in Patients With Critical Limb Ischemia

2014 ◽  
Vol 34 (suppl_1) ◽  
Author(s):  
Houssam Farres ◽  
Caroline Sutton ◽  
Abba Zubair ◽  
John D Dortch ◽  
Albert Hakaim
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Natriuretic Peptide ◽  
Critical Limb Ischemia ◽  
Limb Ischemia ◽  
Human Model ◽  
Differentiation Potential ◽  
Paracrine Effects ◽  
Ischemic Group ◽  
Vascular Regeneration

Mesenchymal stem cells (MSCs) have been shown to improve regeneration of injured tissues in vivo. Several in vitro studies and animal models have demonstrated improvement in MSCs paracrine effects under hypoxic conditions. Moreover, several studies suggested that the pro B-type natriuretic peptide (pro-BNP) could be involved in the stimulation of postischemic vascular regeneration. The purpose of this study was to investigate the effect of critical limb ischemia, in a human model, on in-situ adipose derived mesenchymal stem cells (ADMSCs) and to determine whether serum levels of N-terminal pro-BNP correlate with ADMSCs counts and associated paracrine effects. Lipoaspirate samples of ≥ 10mL were collected from ischemic limbs (ischemic group) and compared to control (without ischemia). MSCs were characterized by frequency, viability, differentiation potential, cytokines expression, and cell surface markers. Serum NT pro-BNP was measured as well. MSCs counts were 9-to-10-fold higher in patients with ischemic limbs (mean 7952 MSC/mL ± 542) than controls (mean 790 MSC/mL ± 65). Pro-BNP levels (1878-4757 pg/mL) were approximately 8-to-26-fold higher than in age- and sex-matched controls. Furthermore, there were positive correlations between pro-BNP levels and MSCs counts in the ischemic group. In conclusion, patients with critical limb ischemia (CLI) have higher levels of pro-BNP and MSCs counts than controls. Increased levels of pro-BNP and MSCs counts can be considered humoral and cellular surrogates of ischemia and hypoxia in patients with CLI. This supports recent studies that suggest that the increase production of peripheral BNP may be a stem cells-mediated response to stimulate angiogenesis in the ischemic skeletal muscles.

Sign in / Sign up

Export Citation Format

Share Document